Item 5.02 Departure of Director or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) In a Form 8-K filed on March 1, 2012, Galectin Therapeutics Inc. (the "Company") reported that it entered into an Amended Employment Agreement with Maureen E. Foley, the Company's Chief Operating Officer, dated March 1, 2012 (the "March 2012 Agreement"), which superseded the Amended Employment Agreement, dated March 6, 2011, between Ms. Foley and the Company (the "Prior Agreement"). The March 2012 Agreement extended the term of the Prior Agreement from March 6, 2012 to June 30, 2012.

On July 19, 2012, the Company and Ms. Foley entered into an Amended Employment Agreement effective as of July 1, 2012 (the "July 2012 Agreement"), which extended the term of the March 2012 Agreement from June 30, 2012, to September 30, 2012, and, subject to approval of the Compensation Committee of the Company's Board of Directors, amended the vested stock options held by Ms. Foley to enable exercise for their full term by deleting the requirement that they terminate 90 days after employment unless previously exercised.

The foregoing description of the July 2012 Agreement is a summary only and is qualified by reference to the full text of the July 2012 Agreement, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.:

10.1 Amended Employment Agreement entered into July 19, 2012, between Galectin Therapeutics Inc. and Maureen Foley

---